Mannose-modified hyaluronic acid nanocapsules for the targeting of tumor-associated macrophages.
Iago Fernández-MariñoClément AnfrayJosé Crecente-CampoAkihiro MaedaAldo UmmarinoCarmen Teijeiro-ValiñoDario Blanco-MartinezFrancis MpambaniLaurence PoulJulie DevalliereMatthieu GermainJuan CorreaMarcos Fernandez-VillamarinPaola AllavenaEduardo Fernandez-MegiaMaría José AlonsoFernando Torres AndónPublished in: Drug delivery and translational research (2022)
Tumor-associated macrophages (TAMs), a class of immune cells that play a key role in tumor immunosuppression, are recognized as important targets to improve cancer prognosis and treatment. Consequently, the engineering of drug delivery nanocarriers that can reach TAMs has acquired special relevance. This work describes the development and biological evaluation of a panel of hyaluronic acid (HA) nanocapsules (NCs), with different compositions and prepared by different techniques, designed to target macrophages. The results showed that plain HA NCs did not significantly influence the polarization of M0 and M2-like macrophages towards an M1-like pro-inflammatory phenotype; however, the chemical functionalization of HA with mannose (HA-Man) led to a significant increase of NCs uptake by M2 macrophages in vitro and to an improved biodistribution in a MN/MNCA1 fibrosarcoma mouse model with high infiltration of TAMs. These functionalized HA-Man NCs showed a higher accumulation in the tumor compared to non-modified HA NCs. Finally, the pre-administration of the liposomal liver occupying agent Nanoprimer™ further increased the accumulation of the HA-Man NCs in the tumor. This work highlights the promise shown by the HA-Man NCs to target TAMs and thus provides new options for the development of nanomedicine and immunotherapy-based cancer treatments.